Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression-Reference-Cited by-同舟云学术

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression

Published:2019-09-01 Issue:9 Volume:76 Page:893
ISSN:2168-622X
Container-title:JAMA Psychiatry
language:en
Short-container-title:JAMA Psychiatry

Author:

Daly Ella J.¹,Trivedi Madhukar H.²,Janik Adam³,Li Honglan¹,Zhang Yun⁴,Li Xiang⁵,Lane Rosanne⁶,Lim Pilar⁶,Duca Anna R.¹,Hough David¹,Thase Michael E.⁷,Zajecka John⁸,Winokur Andrew⁹¹⁰,Divacka Ilona¹¹,Fagiolini Andrea¹²,Cubala Wieslaw J.¹³,Bitter István¹⁴,Blier Pierre¹⁵,Shelton Richard C.¹⁶,Molero Patricio¹⁷,Manji Husseini¹,Drevets Wayne C.³,Singh Jaskaran B.³

Affiliation:

1. Department of Neuroscience, Janssen Research and Development LLC, Titusville, New Jersey

2. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas

3. Department of Neuroscience, Janssen Research and Development LLC, San Diego, California

4. Department of Clinical Biostatistics, Janssen Research and Development LLC, Fremont, California

5. Department of Clinical Biostatistics, Janssen Research and Development LLC, Raritan, New Jersey

6. Department of Clinical Biostatistics, Janssen Research and Development LLC, Titusville, New Jersey

7. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia

8. Department of Psychiatry, Rush University Medical Center, Chicago, Illinois

9. Department of Psychiatry, University of Connecticut Health, Farmington

10. Institute of Living, Hartford, Connecticut

11. Private practice, Prague, Czech Republic

12. Department of Molecular Medicine, Division of Psychiatry, University of Siena, Siena, Italy

13. Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland

14. Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

15. Departments of Psychiatry and Cellular/Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada

16. Department of Psychiatry, University of Alabama School of Medicine, Birmingham

17. Department of Psychiatry, Clinica Universidad de Navarra, Pamplona, Spain

Publisher

American Medical Association (AMA)

Subject

Psychiatry and Mental health

Link

https://jamanetwork.com/journals/jamapsychiatry/article-pdf/76/9/893/17851981/jamapsychiatry_daly_2019_oi_190033.pdf

Reference27 articles.

1. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis.;Walker;JAMA Psychiatry,2015

2. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.;Rush;Am J Psychiatry,2006

3. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.;Newport;Am J Psychiatry,2015

4. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.;Zarate;Arch Gen Psychiatry,2006

5. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.;Murrough;Am J Psychiatry,2013

Cited by 441 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression;Biomarkers in Neuropsychiatry;2024-12

2. Psychometric properties of the 23-Item Clinician Administered Dissociative States Scale (CADSS) in a psychological trauma population;Journal of Affective Disorders;2024-11

3. Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray;International Journal of Psychiatry in Clinical Practice;2024-09-02

4. Newer Treatments for Mood and Anxiety Disorders;Medical Clinics of North America;2024-09

5. Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs;Psychiatry Research;2024-09